ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: PP14

Putting Lived Experience into Action: Flipping the Script on Living with a Chronic Disease
Abstract Number: 2467

Quadriceps Muscle Fat Composition but Not Muscle Energetics Is Associated with Knee Osteoarthritis: Initial Results from the Study of Muscle, Mobility, and Aging
Abstract Number: 0613

Quantification of Skin Hardness of Patients with Systemic Sclerosis Using SOFTGRAM
Abstract Number: 0032

Quantification of the Escape from X Chromosome Inactivation with the Million Cell-scale Human Blood Single-cell RNA-seq Datasets Reveals Heterogeneity of Escape Across Immune Cells and Escape in the Autoimmune Disease Conditions
Abstract Number: 1864

Quantifying Inflammation: A Novel In-Vivo Total Body PET Imaging Tool to Determine the Kinetics of the Degree of Changes in Inflammation in Different Time Points
Abstract Number: 1757

Quantitative Assessment of Synovial Vascularity Using Power Doppler Index in Rheumatoid Arthritis and Psoriatic Arthritis Patients with High Disease Activity
Abstract Number: 0664

Quantitative Hand Held Dynamometry to Assess Muscle Strength in Scleroderma Associated Myopathy
Abstract Number: 1959

Quantitative Scoring of High Resolution Chest Computed Tomography (HRCT) Images in Myositis and Antisynthetase Syndrome Related Interstitial Lung Disease in Comparison to Scleroderma Related Interstitial Lung Disease
Abstract Number: 1329

R851, a Potent Second Generation IRAK1 and IRAK4 Inhibitor Suppresses IL-6 in Vitro and in Vivo for the Treatment of Rheumatoid Arthritis
Abstract Number: 0081

RA Disease Activity Influence the Frequency and Phenotype of Citrulline Reactive CD4 T Cells in DRB1*04:04 ACPA+ RA Patients
Abstract Number: 0054

RA Monocytes and Monocyte-Derived Macrophages Display Heightened Inflammatory Responses, Reduced Endocytic Capacity and Distinct TET Expression Compared to PsA Monocytes
Abstract Number: 0909

Rab4A Controls the Depletion of IL-2 in CD4+ T Cells via Enhanced CD38 Expression: Potential Involvement in Proinflammatory Lineage Development in Systemic Lupus Erythematosus
Abstract Number: 0999

Race, Payer, and Hospital Factors Are Associated with Post-primary Total Hip Arthroplasty Healthcare Utilization
Abstract Number: 2087

Racial and Ethnic Diversity in Pediatric Fellowships: Fortifying the Pipeline
Abstract Number: 1021

Racial Disparities Between Black and White Patients in Joint Replacement Surgery: A Systematic Review

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].